重组人TNK组织型纤溶酶原激活剂与尿激酶静脉溶栓治疗急性心肌梗死患者的效果比较  

Comparison of effects of recombinant human TNK tissue-type plasminogen activator and urokinase intravenous thrombolysis in treatment of patients with acute myocardial infarction

作　　者：辛景超 孙灿灿 XIN Jingchao;SUN Cancan(Department of Pharmacy of the 7th People’s Hospital of Zhengzhou,Zhengzhou 450000 Henan,China;Department of Pharmacy of the People’s Hospital of Zhengzhou,Zhengzhou 450000 Henan,China)

机构地区：[1]郑州市第七人民医院药学部,河南郑州450000 [2]郑州人民医院药学部,河南郑州450000

出　　处：《中国民康医学》2025年第4期135-137,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:比较重组人TNK组织型纤溶酶原激活剂(rhTNK-tPA)与尿激酶静脉溶栓治疗急性心肌梗死(AMI)患者的效果。方法:回顾性分析2022年5月至2023年8月郑州市第七人民医院收治的200例AMI患者的临床资料,根据治疗方式不同将其分为对照组与观察组各100例。对照组采用注射用重组人尿激酶原静脉溶栓治疗,观察组采用注射用rhTNK-tPA静脉溶栓治疗。比较两组血管再通率、溶栓结束后终点事件发生率、心肌损伤标志物[肌酸激酶同工酶(CK-MB)、肌红蛋白(MYO)、N-末端脑钠肽前体(NT-proBNP)、超敏肌钙蛋白I(hs-cTnI)]水平、不良反应发生率。结果:观察组血管再通率高于对照组,差异有统计学意义(P<0.05);两组溶栓结束后终点事件发生率比较,差异无统计学意义(P>0.05);治疗后,两组CK-MB、MYO、hs-cTnI、NT-proBNP水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:rhTNK-tPA静脉溶栓治疗AMI患者可提高血管再通率,以及降低心肌损伤标志物水平的效果优于重组人尿激酶原静脉溶栓治疗。Objective:To compare effects of recombinant human TNK tissue-type plasminogen activator(rhTNK-tPA)and urokinase intravenous thrombolysis in patients with acute myocardial infarction(AMI).Methods:The clinical data of 200 patients with AMI admitted to the 7th People’s Hospital of Zhengzhou from May 2022 to August 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,100 cases in each group.The control group was treated with intravenous thrombolysis with recombinant human urokinase for injection,while the observation group was treated with intravenous thrombolysis with rhTNK-tPA for injection.The vascular recanalization rate,the incidence of endpoint events after thrombolysis,the levels of myocardial injury markers[creatine kinase isoenzyme(CK-MB),myoglobin(MYO),N-terminal pro-brain natriuretic peptide(NT-proBNP),hypersensitive troponin I(hs-cTnI)],and the incidence of adverse reactions were compared between the two groups.Results:The vascular recanalization rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of endpoint events after thrombolysis between the two groups(P>0.05).After the treatment,the levels of CK-MB,MYO,hs-cTnI and NT-proBNP in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Intravenous thrombolysis with rhTNK-tPA can improve the vascular recanalization rate and reduce the levels of myocardial injury markers in the patients with AMI.Moreover,it is superior to recombinant human urokinase intravenous thrombolytic therapy.

关 键 词：重组人TNK组织型纤溶酶原激活剂 尿激酶 急性心肌梗死 血管再通率 心肌损伤标志物 不良反应 

分 类 号：R541.4[医药卫生—心血管疾病]